PRPH ProPhase Labs Inc

ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025

ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025

GARDEN CITY, NY, May 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, announced today that they will be presenting first quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on May 20, 2025, at 10:00 am EDT. Ted Karkus, CEO, looks forward to providing shareholders with an update on several positive activities, including the initiative to sell the Company’s wholly owned subsidiary, Nebula Genomics, and the Crown Medical Collections initiative to collect tens of millions of dollars in accounts receivable.

A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.

Investors interested in participating in this live event will need to register using the link below. After the event, a replay will be available on The Company’s investor website.

REGISTER HERE:

  • To ensure smooth connectivity, please access this link using the latest version of Google Chrome.

About ProPhase Labs Inc.

ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development – such as our potentially life-saving test for the early detection of esophageal cancer – and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value.

Media Relations and Institutional Investor Contact:

ProPhase Labs, Inc.

Retail Investor Relations Contact:

Renmark Financial Communications Inc.

John Boidman:

Tel.: (416) 644-2020 or (212) 812-7680



EN
13/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ProPhase Labs Inc

 PRESS RELEASE

ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on ...

ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025 GARDEN CITY, NY, May 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, announced today that they will be presenting first quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on May 20, 2025, at 10:00 am EDT. Ted Karkus, CEO, looks forward to providing shareholders with an update on several positive activities, including the initiative to sell the Company’s wholly...

 PRESS RELEASE

ProPhase Labs, Inc. Announces Financial Results for the Year Ended Dec...

ProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024 Company to Accelerate BE-Smart Commercialization as a Cash-Pay Diagnostic Significantly reduces overhead, improves margins heading into Q2 2025 Company to hold a conference call Monday, March 31, 2025, at 11:00 AM EST GARDEN CITY, NY, March 31, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today reported its financial and operational results for the full-year ended December 31, 2024 and outl...

 PRESS RELEASE

ProPhase Labs Inc. to Present 2024 Year End Financial Results on March...

ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025 GARDEN CITY, NY, March 27, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today announced that they will be presenting full year 2024 financial results, and a review of current Company strategy, on a virtual conference call hosted by Renmark Financial on March 31, 2025 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welco...

 PRESS RELEASE

ProPhase Labs to Present at the Investor Summit Virtual on March 11

ProPhase Labs to Present at the Investor Summit Virtual on March 11 GARDEN CITY, NY, March 07, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer products company, today announced that Ted Karkus, CEO, will be presenting at this year’s Investor Summit Virtual on March 11th. Event: Q1 Investor SummitPresentation Time: 1:30 P.M. ET Location: Conference Overview and StructureThe Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be...

 PRESS RELEASE

ProPhase Labs Examines Strategic Opportunities to Leverage Its DTC Mul...

ProPhase Labs Examines Strategic Opportunities to Leverage Its DTC Multi-Media Infrastructure with Telehealth Physician Networks for Prescription Drugs Company Announces Ongoing Strategic Cost Cutting to Focus Resources on new DTC Marketing Initiatives to Drive Growth and Profitability Dispels rumors of an Investment Bank initiating a Capital Raise GARDEN CITY, NY, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and consumer products company provides a Company update and schedules a conference call ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch